Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04954664 · ClinicalTrials.gov registry record · NA

Ridge Augmentation Using Allograft Particles Hydrated With or Without Recombinant Human Platelet-Derived Growth Factor

A NA study of Bone Loss and Dental Implant, sponsored by University of Alabama at Birmingham.

Recruiting
Registry status
NA
Development phase
44
Enrollment target
1
Study location

NCT04954664: Recruiting NA study of Bone Loss and Dental Implant, sponsored by University of Alabama at Birmingham.

NCT04954664 is a NA study of Bone Loss and Dental Implant that is actively recruiting participants, run by University of Alabama at Birmingham. The registered enrollment target is 44 participants, below the 252-participant average among 16 other Bone Loss trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04954664, a NA study of Bone Loss and Dental Implant, is actively recruiting participants, sponsored by University of Alabama at Birmingham.

RECRUITING
Registry status
NA
Development phase
44 participants
Enrollment target
1
Study location

Study Summary

This study will compare two techniques to achieve increase in ridge dimensions as a preparation for dental implants using a resorbable barrier membrane and bone particulate allogenic graft hydrated with saline or a growth factor called Recombinant Human Platelet-Derived Growth Factor (rhPDGF).

Primary Outcome

To quantify the distribution of the different tissues (new bone, soft tissue, residual graft and artifact) after 4 months of healing. Hence, the primary outcome will be the new bone formation, defined as the percentage of new bone area in the histomorphometric sections.

Conditions Studied

Interventions

  • BIOLOGICAL Allograft particles hydrated with rhPDGF
  • BIOLOGICAL Allograft particles hydrated in a conventional way with saline.

Study Locations (1)

Alabama

  • Unversity of Alabama at Birmingham, School of Dentistry - Birmingham

Trial Details

FieldValue
Enrollment Target 44 participants
Start Date 2021-08-11
Est. Completion 2027-12
Phase NA
University of Alabama at Birmingham

1,160 total trials

What NCT04954664 shows while recruiting

NCT04954664 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 44 participants, a relatively small participant target, below the 252-participant average among 16 other Bone Loss trials with a reported enrollment target (83% lower).

The record links to 2 conditions, with Bone Loss appearing as the primary indexed condition, and to 2 interventions - of which Allograft particles hydrated with rhPDGF is the first listed.

NCT04954664 reports a single indexed study location in Alabama.

Frequently Asked Questions

What is clinical trial NCT04954664 about?

NCT04954664 is a clinical study titled "Ridge Augmentation Using Allograft Particles Hydrated With or Without Recombinant Human Platelet-Derived Growth Factor". This study will compare two techniques to achieve increase in ridge dimensions as a preparation for dental implants using a resorbable barrier membrane and bone particulate allogenic graft hydrated with saline or a growth factor called Recombinant Human Platelet-Derived Growth Factor (rhPDGF).

What is the current status of trial NCT04954664?

This trial is currently recruiting. It is a NA study. The enrollment target is 44 participants. The study started on 2021-08-11. Estimated completion is 2027-12.

What conditions does trial NCT04954664 study?

This clinical trial studies the following conditions: Bone Loss, Dental Implant.

What interventions are being tested in trial NCT04954664?

The interventions under investigation include: Allograft particles hydrated with rhPDGF (BIOLOGICAL), Allograft particles hydrated in a conventional way with saline. (BIOLOGICAL).

Who is sponsoring clinical trial NCT04954664?

This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04954664 being conducted?

This trial has 1 study location across Alabama. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Bone Loss

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04954664's enrollment target sits among peer trials

44 12th of 16 higher than 5 of 16 other Bone Loss trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Bone Loss trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02323945 · 44 participants · NA

    Effects of Breathing Mild Bouts of Low Oxygen on Limb Mobility After Spinal Injury

  • NCT03093909 · 44 participants · Phase 1

    Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases

  • NCT03104491 · 44 participants · Phase 1

    Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia

  • NCT03781765 · 44 participants · Phase 4

    Stimulant vs. Non-stimulant Treatments and Reward Processing in Drug-naive Youth at SUD Risk

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04954664, the US trial registry maintained by the National Library of Medicine. NCT04954664 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.